- Email: [email protected]
State of the art and umbilical cord transplants
126
Proceedings of the 23rd Annual APON Conference
treatment and nursing staff to ascertain feedback on content level and categories of information included on the instruction sheets. The compiled list of drug sheets needing revision or development was divided among the adult and pediatric nursing staff members. Simultaneously, the workgroup reviewed, revised, and created standard sentences for drug actions, side effects, and special instructions using the National Cancer Institute guidelines for writing patient educational materials and paying attention to layout, t y p e size and style, text arrangement, and content. Drafts from the nursing staff were submitted, and the workgroup revised each sheet for accuracy, content completeness, and format consistency. The sheets were then reviewed by a multidisciplinary team consisting of pharmacists, clinical trial principal investigators, and research nurses to further ensure the accuracy of the documents. F e e d b a c k was incorporated. Because this program contains a large number of drug and s y m p t o m management sheets, the workgroup decided to pilot the program by releasing revised and new sheets in small groups as they were completed. Once the entire program is completed, it will be submitted to the Nursing Department Shared Governance Committee for approval and placement on the Intranet. This poster explores the strategies used to revamp a chemotherapy teaching series at a time when better quality educational tools are needed and manpower hours are short. The historical overview of this project, examples of sheets, pitfalls, and limitations will be shared.
References Cooley, M.E., Moriaty, H., Berger, M.S., Selm-Orr, D., Coyle, B., & Short, T. (1995). Patient literacy and readability of written cancer education materials. Oncology Nursing Forum 22, 1345-51. Doak, L.G., Doak, C.C., & Meade, C.D. (1996). Strategies to improve cancer education materials. Oncology Nursing Forum 23, 1305-12. United States Department of Health and Human Services. (1995). Clear and simple: Developing effective print material for low-literate readers. (NIH Publication No. 95-3594). Bethesda, MD: Author.
State of the Art and Umbilical Cord Transplants T r a c y Callahan, B S N , RN, A m a n d a J o h n s o n , MSN, RN, Michelle Frey, MS, RN, A O C N , J o a n n e Kurtzberg, MD; Pediatric S t e m Cell T r a n s p l a n t P r o g r a m , D u k e University M e d i c a l Center, D u r h a m , NC Unrelated umbilical cord blood transplantation (UCBT) is one of the most recent developments that has earned recognition in the treatment of children with selected metabolic, genetic, and oncologic diseases. Cord blood is a rich source of stem cells and has b e c o m e an ever-growing alternative to conventional bone marrow transplantation due to the limited availability of suitable bone marrow donors (especially in minority populations who have a lower probability of finding a matched donor). Clinical results demonstrate that UCBT is associated with a high probability of engraftment and causes less graft-versus-host disease than allogeneic bone marrow. Other benefits of UCBT include (a) its rapid availability, (b) absence of risk to the donor, and (c) low risk of transmittable infectious diseases. The Duke Pediatric Stem Cell Program was the recipient of two cord blood contracts in 1996: one for UCBT and the other for a cord blood bank. These contracts were established in 1998 and to date the Pediatric Stem Cell Program at Duke has performed more than 185 unrelated cord blood transplants. In 1993 Duke was the first institution to perform an unrelated UCBT. The purpose of this poster is to educate the pediatric oncology/bone marrow transplant nurse about unrelated UCBT. The key objectives will be as follows: 1. Identify the indications for cord blood transplantation. 2. Illustrate the process for harvesting umbilical cord blood. 3. Describe the risks, benefits, and side effects of cord blood transplantation. 4. Review the nursing care and implications associated with patients undergoing cord blood transplantation.
Proceedings of the 23rd Annual APON Conference
treatment and nursing staff to ascertain feedback on content level and categories of information included on the instruction sheets. The compiled list of drug sheets needing revision or development was divided among the adult and pediatric nursing staff members. Simultaneously, the workgroup reviewed, revised, and created standard sentences for drug actions, side effects, and special instructions using the National Cancer Institute guidelines for writing patient educational materials and paying attention to layout, t y p e size and style, text arrangement, and content. Drafts from the nursing staff were submitted, and the workgroup revised each sheet for accuracy, content completeness, and format consistency. The sheets were then reviewed by a multidisciplinary team consisting of pharmacists, clinical trial principal investigators, and research nurses to further ensure the accuracy of the documents. F e e d b a c k was incorporated. Because this program contains a large number of drug and s y m p t o m management sheets, the workgroup decided to pilot the program by releasing revised and new sheets in small groups as they were completed. Once the entire program is completed, it will be submitted to the Nursing Department Shared Governance Committee for approval and placement on the Intranet. This poster explores the strategies used to revamp a chemotherapy teaching series at a time when better quality educational tools are needed and manpower hours are short. The historical overview of this project, examples of sheets, pitfalls, and limitations will be shared.
References Cooley, M.E., Moriaty, H., Berger, M.S., Selm-Orr, D., Coyle, B., & Short, T. (1995). Patient literacy and readability of written cancer education materials. Oncology Nursing Forum 22, 1345-51. Doak, L.G., Doak, C.C., & Meade, C.D. (1996). Strategies to improve cancer education materials. Oncology Nursing Forum 23, 1305-12. United States Department of Health and Human Services. (1995). Clear and simple: Developing effective print material for low-literate readers. (NIH Publication No. 95-3594). Bethesda, MD: Author.
State of the Art and Umbilical Cord Transplants T r a c y Callahan, B S N , RN, A m a n d a J o h n s o n , MSN, RN, Michelle Frey, MS, RN, A O C N , J o a n n e Kurtzberg, MD; Pediatric S t e m Cell T r a n s p l a n t P r o g r a m , D u k e University M e d i c a l Center, D u r h a m , NC Unrelated umbilical cord blood transplantation (UCBT) is one of the most recent developments that has earned recognition in the treatment of children with selected metabolic, genetic, and oncologic diseases. Cord blood is a rich source of stem cells and has b e c o m e an ever-growing alternative to conventional bone marrow transplantation due to the limited availability of suitable bone marrow donors (especially in minority populations who have a lower probability of finding a matched donor). Clinical results demonstrate that UCBT is associated with a high probability of engraftment and causes less graft-versus-host disease than allogeneic bone marrow. Other benefits of UCBT include (a) its rapid availability, (b) absence of risk to the donor, and (c) low risk of transmittable infectious diseases. The Duke Pediatric Stem Cell Program was the recipient of two cord blood contracts in 1996: one for UCBT and the other for a cord blood bank. These contracts were established in 1998 and to date the Pediatric Stem Cell Program at Duke has performed more than 185 unrelated cord blood transplants. In 1993 Duke was the first institution to perform an unrelated UCBT. The purpose of this poster is to educate the pediatric oncology/bone marrow transplant nurse about unrelated UCBT. The key objectives will be as follows: 1. Identify the indications for cord blood transplantation. 2. Illustrate the process for harvesting umbilical cord blood. 3. Describe the risks, benefits, and side effects of cord blood transplantation. 4. Review the nursing care and implications associated with patients undergoing cord blood transplantation.